Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma
NCT04590248Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of adavosertib in uterine serous carcinoma (USC), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate up to 75 weeks. Started Nov 2020; status: completed.
02
Drugs
adavosertib
03
Conditions
uterine serous carcinoma (USC)
Beyond the preview
Go deeper on NCT04590248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590248.